Topic: central nervous system
Roland Bürli, Ph.D., jois Cerevance as the CNS-focused biotech looks to advance a suite of treatments for Parkinson’s and Alzheimer’s disease.
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.
Passage Bio reeled in $115.5 million, which will support the development of five programs aimed at treating rare monogenic central nervous system diseases.
J&J’s new antidepressant esketamine comes in front of an FDA advisory committee tomorrow, hoping to end a drought in novel therapies for the disorder.
Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its bid to become a player at the cutting edge of genetic medicine.
Sosei Heptares is partnering with venture fund Medicxi to form two companies focusing on orexin agonist drugs for neurological diseases.
Biogen’s unwillingness to talk about interim phase 3 data for its Alzheimer’s drug aducanumab is spooking investors.
A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.
Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.
The partners will work to develop adeno-associated virus vectors capable of crossing the blood-brain barrier.